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Despite a dearth of new agents currently being developed to combat multidrug-resistant Gram-negative pathogens, the combi-
nation of ceftolozane and tazobactam was recently approved by the Food and Drug Administration to treat complicated intra-
abdominal and urinary tract infections. To characterize the activity of the combination product, time-kill studies were con-
ducted against 4 strains of Escherichia coli that differed in the type of -lactamase they expressed. The four investigational
strains included 2805 (no-lactamase), 2890 (AmpC-lactamase), 2842 (CMY-10 -lactamase), and 2807 (CTX-M-15 -lacta-
mase), withMICs to ceftolozane of 0.25, 4, 8, and>128 mg/liter with no tazobactam, andMICs of 0.25, 1, 4, and 8mg/liter with 4
mg/liter tazobactam, respectively. All four strains were exposed to a 6 by 5 array of ceftolozane (0, 1, 4, 16, 64, and 256 mg/liter)
and tazobactam (0, 1, 4, 16, and 64mg/liter) over 48 h using starting inocula of 106 and 108 CFU/ml. While ceftolozane-tazobac-
tam achieved bactericidal activity against all 4 strains, the concentrations of ceftolozane and tazobactam required for a>3-log
reduction varied between the two starting inocula and the 4 strains. At both inocula, the Hill plots (R2> 0.882) of ceftolozane
revealed significantly higher 50% effective concentrations (EC50s) at tazobactam concentrations of<4 mg/liter than those at
concentrations of>16 mg/liter (P< 0.01). Moreover, the EC50s at 10
8 CFU/ml were 2.81 to 66.5 times greater than the EC50s at
106 CFU/ml (median, 10.7-fold increase; P 0.002). These promising results indicate that ceftolozane-tazobactam achieves bac-
tericidal activity against a wide range of -lactamase-producing E. coli strains.
The rising prevalence of multidrug-resistant (MDR) Gram-negative organisms has forced urgent efforts to expand the
therapeutic armamentarium against these problematic patho-
gens. Recent endeavors to develop new cephalosporin com-
pounds exhibiting promising antipseudomonal activity led to the
discovery of ceftolozane (ceftolozane, previously designated
CXA-101 or FR264205) (1). This novel agent has been credited
with enhanced stability to popular chromosomally mediated
cephalosporin resistancemechanisms (including hyperexpression
of AmpC -lactamase enzymes and efflux pumps) (2), with a low
propensity for cross-resistance to other cephalosporins to arise (3).
Antimicrobial inactivation arising from transferable plasmid-
mediated -lactamase hydrolysis presents the principal basis of
-lactam resistance among Enterobacteriaceae. More than 850
structurally diverse -lactamase enzymes have been identified to
date and classified as groups A to D based on their amino acid
sequence homology (4). Worryingly, the rapid emergence of ex-
tended-spectrum--lactamase-producing Escherichia coli strains
in recent times has been implicated in community-onset infec-
tions as a significant cause of morbidity, mortality, and health
care-related costs. Despite ceftolozane’s intrinsic benefits over
other cephalosporins, the inability of the compound to overcome
extended-spectrum -lactamases (ESBLs) has been documented
(5–7). To ameliorate this deficiency, the addition of the -lacta-
mase inhibitor tazobactam to ceftolozane extends the spectrum of
activity of ceftolozane (8). The resulting ceftolozane-tazobactam
combination was found to display remarkable activity against a
range of MDR Gram-negative species (7) and was subsequently
approved by the Food and Drug Administration to treat compli-
cated intra-abdominal and urinary tract infections in adults (9).
Although the activity of ceftolozane-tazobactam against E. coli
has been characterized in prior in vitro studies (10–12), a system-
atic analysis of the combination’s performance against strains
producing different -lactamases has yet to be investigated at
multiple levels of bacterial burden. Therefore, integrating antimi-
crobial pharmacokinetics (PK) and pharmacodynamics (PD) to
effectively evaluate the bacteriologic response to ceftolozane-tazo-
bactam is warranted (13). Our objective was to utilize time-kill
studies to characterize the bacterial killing effects of ceftolozane
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and tazobactam alone and in combination against different-lac-
tamase-producing E. coli strains.
MATERIALS AND METHODS
Bacterial strains. The four isogenic strains of E. coli employed for this
study were engineered by Merck & Co. to differentially express a single
-lactamase; these included (i) 2805 (wild type, no-lactamase), (ii) 2890
(AmpC -lactamase), (iii) 2842 (CMY-10 -lactamase), and (iv) 2807
(CTX-M-15 -lactamase) (Table 1). -Lactamase expression was modu-
lated by assembly of the enzyme open reading frame per published
GenBank sequences (strain 2890, Pseudomonas aeruginosa AmpC and
ampR [5= region], GenBank accession no. X54719.1; strain 2842, E. coli
K998298 ESBL precursor [blaCMY-10], GenBank no. AF381617.1; strain
2807, E. coli strain 405/06 plasmid pKC405 -lactamase CTX-M-15
[blaCTX-M-15] and insertion sequence IS26 TnpA, Genbank no.
GQ274933.1), insertion into a pBR322 cloning vector (GenBank no.
J0749), and replacement of the blaTEM-1 open reading frame in the -lac-
tamase-deficient E. coli DH10B parent strain. The native blaTEM-1 pro-
moter was included in the modified pBR322 plasmid to regulate the ex-
pression of the desired -lactamase. Prior to experiments, subculture of
2805 was performed on tryptic soy agar (TSA) with 5% sheep blood (BD
Biosciences, Franklin Lakes, NJ), while 2890, 2842, and 2807 were subcul-
tured in the presence of 25g/ml tetracycline to maintain the selection of
plasmids.
Antibiotics, susceptibility testing, and medium. Analytical-grade
ceftolozane and tazobactam powders were obtained from Merck & Co.
(Kenilworth, NJ). Fresh stock solutions were prepared immediately prior
to experiments in Milli-Q water. Standard broth microdilution methods
were adopted from theClinical andLaboratory Standards Institute (CLSI)
(14) for the determination of MICs. The MIC experiments were per-
formed in quadruplicate, while time-kill experiments were performed in
duplicate; all studies were conducted using cation-adjustedMueller-Hin-
ton broth (CaMHB, at 25.0 mg/liter Ca2 and 12.5 mg/liter Mg2; Difco,
Detroit, MI).
Time-kill experiments. Time-kill experiments were performed for
ceftolozane and tazobactam alone and in combination, using previously
described methods (15). Briefly, fresh bacterial colonies from overnight
growth were added to CaMHB to provide a bacterial suspension, which
was dilutedwithCaMHB to achieve the desired starting inoculumof106
or108 CFU/ml in a 50-ml Falcon tube. A 6 by 5 array of ceftolozane (0,
1, 4, 16, 64, and 256mg/liter) and tazobactam (0, 1, 4, 16, and 64mg/liter)
concentrations was tested as monotherapy and in combination over a
period of 48 h. Thus, 30 treatment regimens were examined in total
against each strain at both starting inocula. The choice of studied concen-
trations was based on clinically achievable targets discerned from free-
drug PK profiles in healthy volunteers (16).
Samples were withdrawn at 1, 2, 4, 8, 24, 26, 28, 32, and 48 h after
dosing. Colony counts were performed by plating 50-l aliquots of each
diluted sample onto tryptic soy agar (TSA) plates containing 5% sheep
blood (Becton Dickinson, Franklin Lakes, NJ) using an automated spiral
dispenser (Whitley automatic spiral plater; Don Whitley Scientific Lim-
ited, West Yorkshire, England). Plates were incubated at 37°C for 24 h,
and viable bacterial counts were determined (log10 CFU/ml) using a laser
bacteria colony counter (ProtoCOL version 2.05.02; Synbiosis, Cam-
bridge, England). Bactericidal activity (99.9% kill) was associated with a
3.0-log10 CFU/ml decrease in bacterial density compared to the initial
inoculum at any time. Experiments were conducted over 48 h (as opposed
to the traditional 24-h standard) to provide insight into the pharmacody-
namics of each combination beyond 24 h, and also to better discriminate
between the killing activities of the different ceftolozane and tazobactam
concentrations. As the degradation of ceftolozane and tazobactam at 35°C
was of concern, concentrations of ceftolozane and tazobactam were mea-
sured in the absence of bacteria over 48 h to calculate the rate of degrada-
tion for each agent.
Pharmacodynamic analyses. The bacterial killing effect (E) of mono-
and combination therapies was quantified as the log ratio change in bac-
terial density (CFU/ml) at 48 h versus preantibiotic exposure at 0 h (see
equation 1) (17). Point-based analyses were performed on plots of E ver-
sus ceftolozane concentrations. Taking into consideration the general
mechanism of action of -lactam–-lactam inhibitor combinations
(whereby inhibitors are understood to bind to inactivating -lactamase
enzymes, thus allowing -lactam agents to exert their action), we attrib-
uted the majority of the killing activity exerted by the ceftolozane-tazo-
bactam combination to the effect of ceftolozane. Consequently, using
nonlinear regression, concentration-effect relationships were fit to Hill-
type models for each strain at each fixed tazobactam concentration, ac-
cording to equation 2, where E0 is the measured effect in the absence of
ceftolozane, Emax is the maximal effect, C is the concentration of ceftolo-
zane, EC50 is the concentration at which there is a 50% maximal effect,
andH is theHill constant. Statistical analyses ofEmax and EC50 parameters
were conducted to determine the effect of increasing tazobactam concen-
trations, using a nonparametric Friedman two-way analysis of variance
(ANOVA) with pairwise comparisons (P 0.05). Differences in param-
eter estimates at 106 versus 108CFU/mlwere determined using hypothesis
testing (P 0.05, F-test). All PD analyses and statistical evaluations were
performed using Systat (version 13.00.05; Systat Software, IL).
Log ratio change Log10
CFU49 h
CFU0 h
(1)
E E0
Emax  C
H
EC50
H CH
(2)
RESULTS
MICs and degradation rates.The ceftolozaneMICs of each strain
without tazobactam and in combination with 4 mg/liter tazobac-
tam are presented in Table 1. In the absence of tazobactam, the
wild-type non--lactamase-producing strain 2805 exhibited the
lowest MIC, at 0.25 mg/liter. Strains 2890 and 2842 producing
class C -lactamases exhibited MICs of 4 and 8 mg/liter, respec-
tively, while high resistance to ceftolozane was displayed by the
CTX-M-15-producing strain, 2807, with an MIC of 128 mg/
liter. In the presence of 4mg/liter tazobactam (perCLSI guidelines
[14]), the MICs of all -lactamase-producing strains were re-
duced to 2- to 16-fold.
After 48 h of incubation at 35°C, the degradation rate constants
of ceftolozane ranged from 0.00466 to 0.00679 h1 (half-life
range, 102 to 148 h;R2 0.938). Tazobactam concentrationswere
constant for the duration of the 48-h experiments.
Time-kill experiments. Time-kill profiles illustrating the
change in bacterial density of the four E. coli strains following
exposure to ceftolozane alone and in combination with tazobac-
tam are presented according to fixed tazobactam concentrations
at both 106 and 108 CFU/ml in Fig. 1 and 2, respectively).
Strain 2805 (no -lactamase). For the susceptible strain 2805
at 106 CFU/ml, complete bactericidal activity reaching undetect-
TABLE 1 -Lactamase production and MICs of each strain to
ceftolozane in the absence and presence of tazobactam
Strain
-Lactamase
Ceftolozane MIC with tazobactam
concn of (mg/liter):
Type
Ambler
class (4) 0 1 4 16 64
2805 None 0.25
2890 AmpC C 4 4 1 0.5 0.5
2842 CMY-10 C 8 4 4 1 0.5
2807 CTX-M-15 A 128 128 8 2 1
Soon et al.
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able limits of eradication was achieved within 24 h in response to
monotherapy with 4 mg/liter ceftolozane (6.48 log10 CFU/ml,
Fig. 1A). No improvement in activity was gained at higher con-
centrations or in combination with tazobactam (Fig. 1B to E). At
108 CFU/ml, bactericidal activity was attained at low tazobactam
concentrations (0 to 4 mg/liter) in combination with ceftolozane
at64mg/liter (6.43 to8.33 log10 CFU/ml; Fig. 2A to E), or at
higher tazobactam concentrations of 16 mg/liter in combina-
tion with 16 mg/liter ceftolozane (5.32 to 8.23 log10 CFU/
ml; Fig. 2D and E).
Strain 2890 (AmpC). Rapid activity was demonstrated with
ceftolozane monotherapy at concentrations of 4 to 256 mg/liter
against 2890 at 106 CFU/ml, with a decrease of 2.39 to 3.53
log10 CFU/ml after 4 h, followed by regrowth, whereby bacterial
counts mimicked those of the untreated control within 24 h (Fig.
1F). A concentration-dependent trend toward a greater level of
ceftolozane killing was observed in combination with increasing
tazobactam concentrations. After 48 h, sustained bactericidal ac-
tivity was attained with combinations of4 mg/liter ceftolozane
and16mg/liter tazobactam (3.93 to6.33 log10 CFU/ml, Fig.
1I and J). At 108 CFU/ml, both monotherapy and combination
regimens containing4mg/liter ceftolozaneweremostly inactive
(below0.5 log10 CFU/ml), while bacterial counts were reduced
to undetectable limits with all regimens containing ceftolozane
concentrations of 256 mg/liter (Fig. 2F to J). Bactericidal activity
at 48 h was noted for 64 mg/liter ceftolozane in combination
with 4 mg/liter tazobactam (4.01, 5.65, and 5.18 log10
CFU/ml, Fig. 2H to J, respectively). The arm with 16 mg/liter
ceftolozane was capable of achieving bactericidal activity at 48 h
when in the presence of 16 and 64 mg/liter tazobactam (3.12
and4.09 log10 CFU/ml, respectively).
Strain 2842 (CMY-10). Concentration-dependent enhance-
ment of ceftolozane activity in combination with tazobactam was
similarly observed for strain 2842 at 106 CFU/ml (Fig. 1K to O).
Accordingly, at4 mg/liter tazobactam, activity was negligible in
combination with 1 mg/liter ceftolozane, while bactericidal activ-
ity was noted within 8 h of exposure to 4 mg/liter ceftolozane
(2.94 to 3.23 log10 CFU/ml) andwas followed by rapid regrowth
by 24 h (Fig. 1K to M). However, bacteria were driven below
detectable limits by all monotherapy and combination regimens
containing 16 mg/liter ceftolozane (6.18 log10 CFU/ml; Fig.
1K to O). At 108 CFU/ml, substantial activity at 16 mg/liter
tazobactam was seen in combination with 64 mg/liter ceftolo-
zane (2.28 to5.18 log10 CFU/ml; Fig. 2K to N). At the highest
tazobactam concentration of 64 mg/liter, bactericidal activity was
achieved with 16 mg/liter ceftolozane (4.74 to 5.39 log10
CFU/ml; Fig. 2O).
Strain 2807 (CTX-M-15). Strain 2807 was resistant to all cef-
tolozane monotherapy regimens at both inocula, with bacterial
counts mirroring the control strain after 48 h. Interestingly, tazo-
bactam maintained the ability to enhance activity in a concentra-
tion-dependent manner (Fig. 1 and 2P to T, 106 and 108 CFU/ml,
FIG 1 Change in bacterial burdens of strains 2805 (A to E), 2890 (F to J), 2842 (K toO), and 2807 (P to T) at a low inoculum (106 CFU/ml) over 48 h, following
treatment with ceftolozane (0 to 256 mg/liter) at fixed tazobactam concentrations (0 to 64 mg/liter). The colored curves on each graph represent different
ceftolozane concentrations, including the untreated growth control (black), tazobactam alone (gray), 1 mg/liter (red), 4 mg/liter (blue), 16 mg/liter (pink), 64
mg/liter (green), and 256 mg/liter (purple).
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respectively). Against both inocula, ceftolozane concentrations
of64 mg/liter achieved bactericidal activity at 48 h at a tazobac-
tam concentration of 16 mg/liter (Fig. 1S and 2S, at or
above4.24 and3.07 log10 CFU/ml, respectively). In the pres-
ence of 64 mg/liter tazobactam, ceftolozane concentrations of4
mg/liter achieved bactericidal activity at 48 h against the 106
CFU/ml inoculum (Fig. 1T, at or above 3.97 log10 CFU/ml),
whereas ceftolozane concentrations of 16 mg/liter were re-
quired for bactericidal activity against the 108 CFU/ml inoculum
(Fig. 2T, at or above3.66 log10 CFU/ml).
PK/PD analyses. PK/PD analyses of time-kill data were per-
formed to determine the target concentrations of ceftolozane and
tazobactam associated with optimal activity. PD relationships
were fit to a sigmoidalHill-type function (equation 2), fromwhich
PD parameters were estimated (R2 0.882, Table 2). The ceftolo-
zane-tazobactam PD relationship was primarily defined by Emax
and EC50 parameters, which provide a measure of the maximal
capacity of efficacy and half-maximal potency, respectively.
Across all strains at both inocula, no significant trends were noted
in Emax values with increasing tazobactam concentrations (P 
0.2, ANOVA). However, in the presence of tazobactam, a clear
tendency toward lower EC50 values was demonstrated for all
strains at both inocula (Table 2). Overall, pairwise comparisons
revealed that all EC50 differences at tazobactam concentrations of
0 to 4 mg/liter versus 16 and 64 mg/liter were statistically sig-
nificant (P  0.01, ANOVA). The changes in EC50 as tazobac-
tam concentrations increased from 0 to 4 mg/liter were not
statistically significant, nor was the difference in EC50s at tazo-
bactam concentrations of 16 versus 64 mg/liter (P  0.1,
ANOVA). Hypothesis testing revealed that the EC50s at 10
8
CFU/ml were 2.81 to 66.5 times greater than those at 106
CFU/ml (median, 10.7-fold increase; P 	 0.002, F-test); how-
ever, no significant differences in Emax were observed between
the two inocula (P 	 0.531, F-test).
DISCUSSION
The introduction of ceftolozane-tazobactam has attracted much
interest, with in vitro data providing evidence that this combina-
tion may present a promising addition to the therapeutic arma-
mentarium against a range of Gram-negative pathogens, includ-
ing -lactamase-expressing strains (1–3, 5–8, 18–20). It is well
recognized that appropriate antimicrobial dosing strategies neces-
sitate a solid understanding of PK/PDprinciples to understand the
relationship between the concentration-time profile and antimi-
crobial activity, allowing the design of regimens that maximize
bacterial eradication andminimize the development of resistance.
In the present study, the in vitro activities of an array of ceftolozane
and tazobactam concentrations were tested alone and in combi-
FIG2 Change in bacterial burdens of strains 2805 (A to E), 2890 (F to J), 2842 (K toO), and 2807 (P to T) at a high inoculum (108CFU/ml) over 48 h, following
treatment with ceftolozane (0 to 256 mg/liter) at fixed tazobactam concentrations (0 to 64 mg/liter). The colored curves on each graph represent different
ceftolozane concentrations, which includes the untreated growth control (black), tazobactam alone (gray), 1mg/liter (red), 4mg/liter (blue), 16mg/liter (pink),
64 mg/liter (green), and 256 mg/liter (purple).
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nation in a dynamic fashion over 48 h against four strains of E. coli
expressing different -lactamases. Our study design incorporated
a wide range of concentrations to ensure that all relevant PD pa-
rameters were captured for mathematical modeling purposes in
the future.
The ability of inhibitors to inactivate specific -lactamase en-
zymes varies markedly within and between classes; for tazobac-
tam, irreversible-lactamase inhibition (“suicide inhibition”) has
mainly been demonstrated against pathogens expressing class A
-lactamases, while reduced activity has been reported for those
expressing classes B, C, and D (21). In the present study, however,
the time-kill data provide evidence that ceftolozane activity was
enhanced by the addition of tazobactam in a concentration-de-
pendent manner, which was observed against all -lactamase-
producing strains at both inocula, irrespective of -lactamase ex-
pression (Fig. 1 and 2). This trendwas substantiated by analyses of
PD parameters, which revealed significantly reduced EC50 values
for all strains, indicating that the potency of ceftolozane increased
at both inocula in the presence of increasing tazobactam concen-
trations. Characteristic differences noted in the time-kill profiles
obtained for each strain serve to reinforce the varied extent of
inactivation that tazobactam may pose on different -lactamases
(21). Notably, a 10.7-foldmedian increase in EC50 was observed at
the inoculumof 108 CFU/ml compared to EC50 values at 10
6 CFU/
ml; similar trends have been observed for other -lactam agents
against -lactamase-producing strains in the presence of a high
bacterial load (22–24). Mechanistic explanations for the differen-
tial PDobserved between the two inocula have been hypothesized,
including the possible release of larger quantities of -lactamase
enzymes from lysed bacteria (25), cell-to-cell communication, or
the decreased presence of active penicillin-binding proteins due to
the reduction in bacterial cell wall synthesis at higher bacterial
densities (26, 27). Although the clinical implications of these ob-
servations have yet to be understood, consideration may be given
to the administration of elevated ceftolozane doses when em-
ployed for the treatment of infections that entail a higher bacterial
burden.
Interestingly, despite previous suggestions of improved stabil-
ity of ceftolozane against AmpC -lactamase from Pseudomonas
aeruginosa (2, 7, 28), the exposure of 2890 to ceftolozane mono-
therapy resulted in extensive regrowth, even at extremely high
concentrations (256 mg/liter) far in excess of the MIC (Fig. 1F).
Owing to the relatively stable ceftolozane concentrations used
during the time-killing experiments, regrowth was likely charac-
terized by the amplification of ceftolozane-resistant subpopula-
tions. Indeed, the phenomenon of heteroresistance to colistin
(29), vancomycin (30), and carbapenems (31) has been reported
and defined as the presence of a resistant subpopulation of bacte-
ria within a susceptible strain based onMICs. Although heterore-
sistance has yet to be detected in E. coli, it certainly provides a
plausible explanation for the regrowth observed here (Fig. 1F).
Importantly, for strain 2890, the addition of 4mg/liter tazobactam
to regimens with4 mg/liter ceftolozane resulted in bactericidal
activity by 24 h at 106 CFU/ml (Fig. 1H), although regrowth at a
concentration of 4 mg/liter ceftolozane was observed by 48 h.
Increasing the dose of tazobactam further to 16 mg/liter resulted
in sustained killing at the ceftolozane concentration of 4 mg/liter
up to 48 h (Fig. 1I). Similarly, the addition of16 mg/liter tazo-
bactam to regimens with64 mg/liter ceftolozane achieved bac-
tericidal activity by 48 h in the ceftolozane-resistant strain 2807 at
TABLE 2 Hill plot PD parameter estimates describing the effect of ceftolozane in the presence of increasing tazobactam concentrations (0 to 64 mg/
liter) at low and high inocula
Strain
Tazobactam
concn
(mg/liter)
Low inoculum of ceftolozane (SE) High inoculum of ceftolozane (SE)
E0 Emax H
a EC50 R
2 E0 Emax H
a EC50 R
2
2805 0 2.68 9.16 10.0 1.14 1.00 0.194 (0.343) 8.64 (0.765) 2.46 (0.737) 39.3 (7.58) 0.991
1 2.62 9.10 10.0 0.948 1.00 0.291 (0.275) 8.84 (0.643) 1.91 (0.388) 33.7 (5.36) 0.995
4 2.35 8.83 10.0 0.903 1.00 0.104 (0.451) 8.94 (1.23) 1.49 (0.509) 32.8 (9.27) 0.987
16 2.48 8.96 9.53 0.156 1.00 0.552 (0.645) 9.03 (1.26) 1.00 (0.325) 10.2 (3.47) 0.984
64 1.83 8.31 10.0 0.136 1.00 0.0450 (0.668) 8.25 (1.25) 1.00 (0.357) 9.04 (3.37) 0.980
2890 0 —b — — — — 0.629 (0.456) 10 (4.78) 1.00 (0.735) 52.1 (74.3) 0.993
1 2.61 (0.734) 2.20 (1.12) 1.00 (1.25) 4.44 (5.65) 0.882 0.780 (0.292) 7.32 (0.505) 1.32 (0.271) 68.4 (1.709) 0.938
4 2.40 (1.56) 9.47 (5.25) 1.00 (1.36) 23.5 (34.7) 0.923 0.497 (0.772) 10.0 (5.56) 1.00 (0.922) 66.0 (7.37) 0.970
16 2.51 (0.751) 6.69 (0.87) 3.23 (2.72) 1.45 (0.53) 0.981 0.622 (0.554) 7.11 (1.13) 1.43 (0.689) 16.1 (5.53) 0.981
64 1.96 (1.60) 6.98 (2.07) 5.10 (5.98) 1.27 (1.41) 0.952 0.137 (0.581) 5.81 (0.861) 3.38 (5.64) 12.2 (6.04) 0.970
2842 0 2.93 (0.109) 9.12 (0.140) 10.0 (27.1) 8.52 (1.48) 1.00 0.727 (0.297) 7.37 (2.87) 1.02 (0.478) 88.3 (75.6) 0.989
1 2.95 (0.100) 9.15 (0.143) 4.57 (3.153) 4.81 (0.620) 1.00 0.179 (0.301) 5.28 (0.603) 4.64 (4.41) 28.8 (17.3) 0.985
4 2.70 (0.296) 8.95 (0.435) 2.96 (1.45) 4.67 (0.466) 0.987 0.039 (0.308) 5.33 (0.637) 2.85 (1.28) 28.7 (8.93) 0.983
16 3.10 (0.119) 9.29 (0.100) 10.0 (0.361) 1.04 (0.001) 1.00 0.0451 (0.382) 5.16 (0.806) 2.54 (1.93) 23.1 (8.56) 0.974
64 2.26 (0.003) 8.44 (0.108) 10.0 (0.112) 0.84 (0.013) 1.00 0.929 (0.458) 4.52 (0.678) 1.76 (0.867) 6.82 (2.51) 0.973
2807 0 — — — — — — — — — —
1 2.57 (0.424) 2.00 (4.17) 1.46 (1.95) 34.9 (11.0) 0.986 — — — — —
4 3.17 (0.511) 4.16 (0.748) 0.633 (0.196) 2.34 (0.956) 0.995 — — — — —
16 2.49 (0.551) 7.27 (0.675) 3.25 (1.36) 1.28 0.421) 0.912 0.0530 (0.473) 5.02 (1.71) 1.00 (0.627) 31.8 (25.0) 0.952
64 1.82 (0.738) 7.46 (0.876) 2.24 (2.57) 1.65 (0.642) 0.982 1.61 (2.05) 5.08 (2.67) 1.00 (1.19) 1.10 (1.14) 0.913
a Hill’s constants were constrained between the limits of 1 and 10.
b —, no parameter estimates calculated because there was negligible activity that was not modeled well by a Hill-type function.
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both inocula. Ceftolozane and tazobactam concentrations of 64
mg/liter and 16 mg/liter reflect achievable maximum concentra-
tion of drug (Cmax) values obtained in healthy volunteers receiving
the equivalent of 1.0-g and 0.5-g doses of ceftolozane and tazobac-
tam, respectively, which were the doses investigated in phase III
clinical trials (16, 32, 33). Taken together, these results highlight
the utility of tazobactam to increase the susceptibility of -lacta-
mase-producing E. coli strains to ceftolozane therapy at both in-
ocula.
Although the %Tthreshold has been identified as the PK/PD
index most predictive of the activity of ceftolozane-tazobac-
tam, our results show a clear concentration dependence, with
enhanced killing at elevated ceftolozane concentrations. The
%Tthreshold was first proposed by VanScoy et al. (12) as the
PK/PD index that best described ceftolozane-tazobactam kill-
ing in E. coli strains expressing the CTX-M-15 -lactamase (12).
Further work with E. coli and Klebsiella pneumoniae strains ex-
pressing various -lactamases led to the unifying conclusion that
the percentage of time above the ceftolozane-tazobactam MIC

0.5 is predictive of the combination’s efficacy, regardless of the
-lactamase expression profile of the pathogen (11). An in vivo
study utilizing a neutropenic mouse model corroborated
%Tthreshold as the ideal PK/PD index, and the authors were able
to identify the % time above the MIC (%TMIC) targets required
to achieve specificmagnitudes of bacterial killing (34). In the pres-
ent study, the concentration dependence observed in the time-kill
experiments may partially be ascribed to the elevated bacterial
burden (108 CFU/ml) that exceeded the bacterial load utilized in
previous in vitro (106 CFU/ml) and in vivo (106.2 to 107.1 CFU/ml)
studies (11, 12, 34). The static concentrations used in the current
investigation may also account for some of the discordance with
the results from prior studies. However, previous investigations
evaluating the PK/PD of -lactam–-lactamase inhibitor combi-
nations have asserted that stoichiometric inhibition of -lacta-
mase enzymes is determined by exposure of the inhibitor over
time, which is best predicted by the area under the concentration-
time curve (AUC) (35). A prior study utilizing piperacillin and
tazobactam also found that dose fractionating the administration
of both agents while maintaining the same drug exposure did not
alter the killing of a TEM-producing strain of E. coli (36). The
activity of ceftolozane-tazobactam may therefore not be com-
pletely described by time-dependent killing, and a hybrid index
that accounts for the AUC or Cmax may improve the predictive
capability of the %Tthreshold index.
In summary, we systematically described the concentration-
effect relationship of ceftolozane and tazobactam alone and in
combination, revealing the ability of ceftolozane-tazobactam to
achieve potent bactericidal activity against E. coli strains express-
ing different types of-lactamase enzymes.While these results are
promising, our time-kill studies utilized static concentrations of
ceftolozane-tazobactam, making the extrapolation of our results
into the clinical setting difficult. To the best of our knowledge,
only two studies, by VanScoy et al. (10, 37), have looked at cef-
tolozane-tazobactam in a hollow-fiber infection model. Further
studies evaluating the performance of the combination regimen
against other pathogens containing -lactamase enzymes are
needed to completely understand the niche of ceftolozane-tazo-
bactam among other -lactams.
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